Search results
Consider using ARVs with fewer side effects on BMD, especially with potential renal toxicity linked with bone fragility or renal hypophosphatemia; TDF-sparing regimens using TAF-based treatment or integrase inhibitors can be explored [69,70];
19 mar 2023 · The review was organized into mean headings (prevalence of osteoporosis in HIV population, impact of HIV on the bone, impact of HIV treatment on the bone, endocrine conditions and bone, hepatitis B, hepatitis C and management and prevention of osteoporosis in HIV).
2 wrz 2020 · The evidence of reduced bone mass in treatment-naïve patients indicates that the virus alone directly affects bone homeostasis (9 – 14). Moreover, some reports indicate that low BMD is not completely attributable to HIV infection alone or HIV infection plus treatments with HAART (15 – 23).
HIV Treatment-Associated Bone Loss: HIV treatments have also been linked to bone loss in PLWH, with an estimated 2-6% decrease in BMD during the first 96 weeks of ART, with the most profound bone loss occurring during the first 24 weeks (Hileman et al., 2015).
19 mar 2023 · A few available antiretroviral therapies (ARVs) are also linked with osteoporosis, particularly those involving tenofovir disoproxil fumarate (TDF). HIV and hepatitis C (HCV) coinfection is associated with a greater risk of osteoporosis and fracture than HIV monoinfection.
26 lip 2024 · There are a few data that suggest that tenofovir and indinavir have direct or indirect negative effects on osteoblast function (bone formation), while ritonavir has a negative effect on bone resorption via declining osteoclast differentiation [96,97,98], warranting further research.
20 cze 2022 · People living with HIV (PLWH) are at an increased risk for osteoporosis, a disease defined by the loss of bone mineral density (BMD) and deterioration of bone quality, both of which independently contribute to an increased risk of skeletal fractures.
